A Study of ZG005 in Patients With Advanced Solid Tumors

Launched by SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD · Jan 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ZG005 for patients with advanced solid tumors, which are types of cancer that form in solid organs, like the lungs or breast. The trial is currently recruiting participants and is designed to find the best dose of ZG005 that is safe and effective. It involves three stages, focusing on gradually increasing the dose to see how well it works and confirming the right amount to use in future studies.

To be eligible for this trial, participants need to be between 18 and 70 years old and have a confirmed diagnosis of advanced solid tumors. They should be able to understand the study and agree to participate by signing a consent form. It's important that potential participants do not have certain health issues, such as recent brain tumors or other cancers within the past five years. Those who join the trial can expect to closely monitor their health during the study, and they will be contributing to important research that could help improve cancer treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fully understand the study and voluntarily sign the informed consent form.
• • Male or female 18-70 years of age;
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
• • Life expectancy ≥ 3 months;
• • Histologically or cytologically confirmed diagnosis of advanced solid tumors.
• Exclusion Criteria:
• • Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
• • Any other malignancy within 5 years.